{"database":"iProX","file_versions":[],"scores":null,"additional":{"omics_type":["Proteomics"],"submitter":["Zhongqiu Liu"],"species":["Homo Sapiens"],"full_dataset_link":["http://www.iprox.org/page/project.html?id=IPX0011605000"],"submitter_email":["liuzq@gzucm.edu.cn"],"submitter_affiliation":["Guangzhou University of Chinese Medicine"],"sample_protocol":[""],"repository":["iProX"],"data_protocol":[""],"name_synonyms":["Cancer of the lung, Malignant tumor of lung, Pulmonary Neoplasms, Lung cancer, Lung, human being, Tissue., malignant lung tumor, Neoplasms, Modern, lung cancer, Cancer of Lung, malignant tumor of lung, malignant neoplasm of the lung, somatic, autosomal dominant, Human, Homo sapiens, cancer of lung, proteomic analysis, malignant lung tumour, Nonsmall cell lung cancer, Neoplasm, Malignant lung tumor, malignant tumour of lung, Pulmonary Cancer, Man, Pulmonary cancer, Pulmonary, Lung Cancer, Lung malignant tumors, malignant tumor of the lung, malignant tumour of the lung, malignant lung neoplasm, Man (Taxonomy), Pulmonary Neoplasm, adenocarcinoma of lung, alveolar cell carcinoma, susceptibility to, LNCR, Lung Cancers, Cancers, human, response to tyrosine kinase inhibitor in, nonsmall cell lung cancer, resistance to, Malignant neoplasm of lung, Lung Neoplasm, malignant neoplasm of lung, Modern Man, protection against, Pulmonary Cancers, Cancer of the Lung, lung neoplasm, somatic mutation, Cancer"],"description_synonyms":["Biological Markers, Viral Marker, C20orf14, akr1c2, Surrogate Endpoints, Product, single-organism developmental process, Laboratory, postnatal development, hPrp6, Radiation Therapies, Biochemical, srxy8, ANT-1, Endpoint, growth and development, protein, Serum, Tumor, Tax1bp2, SRXY8, mcdr2, School-Age, Laboratory Markers, DKCB1, Biological, Pharmaceutical Product, HAKRD, BC019196, protein aggregate, preoperative procedures, DD-2, drug resistance, RGD1307103, treatment, NHE-RF, Tissue, MCDR2, Radiotherapies, BMFF, Immune, Markers, JPDI, HEL103, medicine, malignant neoplasm, Pharmaceutical, Viral Markers, disease management, Therapies, Malignancies, Tumors, DD, Therapy, X-ray therapy, Radiation, Viral, Targeted Radiation, Surrogate Endpoint, D8Wsu151e, 72kDa, AKR1C-pseudo, Biochemical Markers, U5-102K, NOP10P, Biologic Marker, SEC61B, EMBRYO SAC DEVELOPMENT ARREST 27, adenocarcinoma of the lung, Benign, Marker, hbab, EDA27, Radiotherapy, School Age, 1190006C12Rik, NPHLOP2, Chemotherapy, Pharmaceutic, General, HBAB, TAX1BP2, AW122942, Populations, EBP50, Pharmacotherapy, End Points, death rate, adenocarcinoma of lung, EBP-50, BABP, Benign Neoplasms, SRP72, radioisotope therapy, non-small cell lung adenocarcinoma, Immunologic, Laboratory Marker, Treatments, Malignant Neoplasms, nonsmall cell adenocarcinoma, babp, Patient, Biochemical Marker, DD|BABP, School-Age Population, AI326121, Proteomes, invasive procedures, bronchogenic lung adenocarcinoma, Radiation Treatments, Targeted Radiation Therapy, Clinical Markers, chemotherapy, Clinical Marker, Neoplasms, drug susceptibility/resistance, Benign Neoplasm, ingls, Gene, Surgery, pharmacotherapy, Pharmacotherapies, protein-containing complex, Malignant, Chemotherapies, BMFS1, Surrogate End Points, Surrogate Markers, nherf1, Gene Products, TOM, MTHr, Drug Therapies, Drugs, School-Age Populations, study, Biomarker, Clinical, Malignancy, Prp6, LUAD, Biological Marker, PDIA19, ERdj5, NHERF, ANT1, Targeted Radiotherapies, Population, RP60, Neoplasias, nherf, ddh2, drugs, Immunologic Markers, nherf-1, Clients, 1110036B12Rik, operative procedures, DDH2, BC032215, Targeted Radiotherapy, Preparation, School Age Population, Immunologic Marker, Biologic, Pharmaceuticals, Cancer, SNRNP102, Products, T13C7.8, Malignant Neoplasm, Targeted Radiation Therapies, Drug resistance, protein complex, NOLA3, Serum Markers, Proteins, Targeted, End Point, total expressed protein, intraoperative procedures, T13C7_8, 2610031L17Rik, Medications, Trx, TRX, Client, Immune Marker, development, Nola3, hakrd, MT, survival, native protein, peroperative procedures, Surrogate End Point, Protein, Resistance, Neoplasm, DD2, dd2, radiation therapy, ArPIKfyve, AI132477, Biologic Markers, Serum Marker, primary cancer, C77589, Pharmaceutic Preparations, Surrogate, operative therapy, Endpoints, response to drug, postnatal growth, 1190003A07Rik, operations, TDD, NHERF-1, patient, Radiation Treatment, Cancers, School Age Populations, malignant tumor, 5730576P14Rik, Surrogate Marker, Drug, Protein Gene Products, Gene Proteins, NHERF1, Preparations, Signal recognition particle 72 kDa protein, lung adenocarcinoma, Therapeutic, AA959718, time of survival., perioperative procedures, Radiation Therapy, Treatment, pharmacologic therapy, Pharmaceutical Products, growth, Neoplasia, Pharmaceutical Preparation, Immune Markers"],"additional_accession":[]},"is_claimable":false,"name":"Proteomic analysis of human lung cancer and paracancer tissues","description":"The treatment of LUAD mainly includes surgery, radiotherapy and chemotherapy. However, the clinical population of LUAD chemotherapy drugs is limited, and patients inevitably have the problem of drug resistance. The development of LUAD therapeutic drugs can provide more treatment strategies for patients, and the study of biomarkers is an effective way to provide potential therapeutic targets. In this study, by comparing the proteome of cancer, paracancer and distant paracancer tissues of LUAD patients, it was found that SEC61B, AKR1C2, NOP10, SLC9A3R1, VAC14, PRPF6, DNAJC10 and SRP72 were eight potential LUAD protein markers. Among them, DNAJC10 has a cancer-promoting effect in LUAD, and its high expression is not conducive to patient survival.","dates":{"publication":"Mon Apr 07 00:00:00 GMT+01:00 2025"},"accession":"PXD062672","cross_references":{"TAXONOMY":["9606"]}}